Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 4, 2009, Pages 245-257

  Jessup, Jewell A ^a   Westwood, Brian M ^a   Chappell, Mark C ^a   Groban, Leanne ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Diastolic function; Fibrosis; Hypertension; Myocardial relaxation; Renin angiotensin system (RAS)

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; LISINOPRIL; LOSARTAN; PHOSPHOLAMBAN; RENIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE RELAXATION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; LEWIS RAT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANIMALS, CONGENIC; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; COLLAGEN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY, DOPPLER; FIBROSIS; HEART RATE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LISINOPRIL; LOSARTAN; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; RATS; RATS, INBRED LEW; RATS, TRANSGENIC; RENIN; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; VENTRICULAR FUNCTION, LEFT;

EID: 68349104175     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709338489     Document Type: Article

References (72)

1. Agabiti-Rosei, E., Muiesan, M.L. and Salvetti, M. (2006) Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy. J Am Soc Nephrol 17: S104-S108.
2. Appleton, C.P., Hatle, L.K. and Popp, R.L. (1988) Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 12: 426-440.
3. Bachmann, S., Peters, J., Engler, E., Ganten, D. and Mullins, J. (1992) Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int 41: 24-36.
4. Baumann, M., Hermans, J.J., Janssen, B.J., Peutz-Kootstra, C., Witzke, O., Heemann, U. et al. (2007 a) Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage. J Hypertens 25: 2504-2511.
5. Baumann, M., Janssen, B.J., Hermans, J.J., Peutz-Kootstra, C., Witzke, O., Smits, J.F. et al. (2007 b) Transient AT 1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 25: 207-215.
6. Baumann, M., Megens, R., Bartholome, R., Dolff, S., van Zandvoort, M.A., Smits, J.F. et al. (2007 c) Prehypertensive renin-angiotensin-aldosterone system blockade in spontaneously hypertensive rats ameliorates the loss of long-term vascular function. Hypertens Res 30: 853-861.
7. Berecek, K.H., Reaves, P. and Raizada, M. (2005) Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats. Vascul Pharmacol 42: 93-98.
8. Bohm, M., Lippoldt, A., Wienen, W., Ganten, D. and Bader, M. (1996) Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 163-164: 217-221.
9. Chappell, M.C. (2007) Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 50: 596-599.
10. Chappell, M.C., Gallagher, P.E., Averill, D.B., Ferrario, C.M. and Brosnihan, K.B. (2003) Estrogen or the AT 1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2.Lewis rat. Hypertension 42: 781-786.
11. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, Jr J.L. et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 289: 2560-2572.
12. Cuspidi, C., Negri, F. and Zanchetti, A. (2008) Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 4: 67-73.
13. Di Bello, V., Giorgi, D., Pedrinelli, R., Talini, E., Palagi, C., Le Donne, M.G. et al. (2004) Left ventricular hypertrophy and its regression in essential arterial hypertension. A tissue Doppler imaging study. Am J Hypertens 17: 882-890.
14. Doulton, T.W., He, F.J. and MacGregor, G.A. (2005) Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45: 880-886.
15. Ferrario, C.M., Jessup, J., Chappell, M.C., Averill, D.B., Brosnihan, K.B., Tallant, E.A. et al. (2005 a) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610.
16. Ferrario, C.M., Jessup, J., Gallagher, P.E., Averill, D.B., Brosnihan, K.B., Ann, T.E. et al. (2005 b) Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 68: 2189-2196.
17. Ferrario, C.M., Trask, A.J. and Jessup, J.A. (2005 c) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290.
18. Flesch, M., Schiffer, F., Zolk, O., Pinto, Y., Stasch, J.P., Knorr, A. et al. (1997) Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 15: 1001-1009.
19. Gagnon, C., Legault, F., Geraldes, P., Tanguay, J.F. and Lambert, C. (2004) Diverse effects of ACE inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 97: 373-381.
20. Gardin, J.M., Drayer, J.I., Weber, M., Rohan, M.K., Knoll, M., Shu, V.W. et al. (1987) Doppler echocardiographic assessment of left ventricular systolic and diastolic function in mild hypertension. Hypertension 9: 1190-1196.
21. Gradman, A.H. and Alfayoumi, F. (2006) From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 48: 326-341.
22. Groban, L., Pailes, N.A., Bennett, C.D., Carter, C.S., Chappell, M.C., Kitzman, D.W. et al. (2006) Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci 61: 28-35.
23. Groban, L., Yamaleyeva, L.M., Westwood, B.M., Houle, T.T., Lin, M., Kitzman, D.W. et al. (2008) Progressive diastolic dysfunction in the female mRen (2).Lewis rat: influence of salt and ovarian hormones. J Gerontol A Biol Sci Med Sci 63: 3-11.
24. Gross, V., Lippoldt, A., Bohlender, J., Ganten, D., Ganten, U. and Luft, F.C. (1996) The renin-angiotensin system and renal function in transgenic (mRen2)27 rats. Exp Nephrol 4(Suppl. 1): 20-26.
25. Hayashida, W., Donckier, J., Van, M.H., Charlier, A.A. and Pouleur, H. (1997) Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Cardiovasc Res 33: 54-62.
26. Izumo, S., Nadal-Ginard, B. and Mahdavi, V. (1988) Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci U S A 85 (2): 339-343.
27. Izumo, S., Lompré, A.M., Matsuoka, R., Koren, G., Schwartz, K., Nadal-Ginard, B. et al. (1987) Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 79 (3): 970-977.
28. Jessup, J.A., Gallagher, P.E., Averill, D.B., Brosnihan, K.B., Tallant, E.A., Chappell, M.C. et al. (2006) Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 291: H2166-H2172.
29. Julius, S., Nesbitt, S.D., Egan, B.M., Weber, M.A., Michelson, E.L., Kaciroti, N. et al. (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354: 1685-1697.
30. Kasner, M., Westermann, D., Steendijk, P., Gaub, R., Wilkenshoff, U., Weitmann, K. et al. (2007) Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116: 637-647.
31. Kawasaki, D., Kosugi, K., Waki, H., Yamamoto, K., Tsujino, T. and Masuyama, T. (2007) Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 71: 524-529.
32. Kolesnyk, I., Dekker, F.W., Noordzij, M., le, C.S., Struijk, D.G. and Krediet, R.T. (2007) Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 27: 446-453.
33. Kunz, R., Friedrich, C., Wolbers, M. and Mann, J.F. (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148: 30-48.
34. Lakhdar, R., Al-Mallah, M.H. and Lanfear, D.E. (2008) Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14: 181-188.
35. Liu, Y.H., Yang, X.P., Shesely, E.G., Sankey, S.S. and Carretero, O.A. (2004) Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol 43: 1473-1480.
36. Luders, S., Schrader, J., Berger, J., Unger, T., Zidek, W., Bohm, M. et al. (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487-1496.
37. Mancia, G., De, B.G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
38. Mann, J.F., Schmieder, R.E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J. et al. (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553.
39. Masuyama, T., Yamamoto, K., Sakata, Y., Doi, R., Nishikawa, N., Kondo, H. et al. (2000) Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 36: 2333-2338.
40. McMurray, J.J., Ostergren, J., Swedberg, K., Granger, C.B., Held, P., Michelson, E.L. et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767-771.
41. Muiesan, M.L., Salvetti, M., Monteduro, C., Rizzoni, D., Corbellini, C., Castellano, M. et al. (2000) Changes in midwall systolic performance and cardiac hypertrophy reduction in hypertensive patients. J Hypertens 18: 1651-1656.
42. Mullins, J.J. and Ganten, D. (1990) Transgenic animals: new approaches to hypertension research. J Hypertens Suppl. 8 (7): S35-S37.
43. Mullins, J.J., Peters, J. and Ganten, D. (1990) Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344: 541-544.
44. Nagueh, S.F., Middleton, K.J., Kopelen, H.A., Zoghbi, W.A. and Quinones, M.A. (1997) Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30: 1527-1533.
45. Nishio, M., Sakata, Y., Mano, T., Yoshida, J., Ohtani, T., Takeda, Y. et al. (2007) Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 25: 455-461.
46. Ohta, K., Kim, S., Wanibuchi, H., Ganten, D. and Iwao, H. (1996) Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR (mRen2)27 transgenic rats. Circulation 94: 785-791.
47. Pearson, A.C., Labovitz, A.J., Mrosek, D., Williams, G.A. and Kennedy, H.L. (1987) Assessment of diastolic function in normal and hypertrophied hearts: comparison of Doppler echocardiography and M-mode echocardiography. Am Heart J 113: 1417-1425.
48. Pendergrass, K.D., Averill, D.B., Ferrario, C.M., Diz, D.I. and Chappell, M.C. (2006) Differential expression of nuclear AT 1 receptors and angiotensin II within the kidney of the male congenic mRen2.Lewis rat. Am J Physiol Renal Physiol 290: F1497-F1506.
49. Pendergrass, K.D., Pirro, N.T., Westwood, B.M., Ferrario, C.M., Brosnihan, K.B. and Chappell, M.C. (2008) Sex differences in circulating and renal angiotensins of hypertensive mRen (2).Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol 295: H10-H20.
50. Periasamy, M. and Janssen, P.M. (2008) Molecular basis of diastolic dysfunction. Heart Fail Clin 4: 13-21.
51. Roig, E., Perez-Villa, F., Morales, M., Jimenez, W., Orus, J., Heras, M. et al. (2000) Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21: 53-57.
52. Rothermund, L., Pinto, Y.M., Vetter, R., Herfort, N., Kossmehl, P., Neumayer, H.H. et al. (2001) Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca2+ handling in hypertensive transgenic rats overexpressing the Ren 2 gene. J Hypertens 19: 1465-1472.
53. Satoh, S., Ueda, Y., Suematsu, N., Oyama, J., Kadokami, T., Sugano, M. et al. (2003) Beneficial effects of angiotensin-converting enzyme inhibition on sarcoplasmic reticulum function in the failing heart of the Dahl rat. Circ J 67: 705-711.
54. Sharma, U., Rhaleb, N.E., Pokharel, S., Harding, P., Rasoul, S., Peng, H. et al. (2008) Novel antiinflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 294: H1226-H1232.
55. Shimizu, M., Ino, H., Okeie, K., Emoto, Y., Yamaguchi, M., Yasuda, T. et al. (2000) Cardiac sympathetic activity in the asymmetrically hypertrophied septum in patients with hypertension or hypertrophic cardiomyopathy. Clin Cardiol 23: 365-370.
56. Smith, R.D., Yokoyama, H., Averill, D.B., Schiffrin, E.L. and Ferrario, C.M. (2008) Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypertension 2: 165-172.
57. Springate, J.E., Feld, L.G. and Ganten, D. (1994) Renal function in hypertensive rats transgenic for mouse renin gene. Am J Physiol 266: F731-F737.
58. Tan, H.W., Zheng, G.L., Li, L., Wang, Z.H., Gong, H.P., Zhang, Y. et al. (2008) Impaired left ventricular synchronicity in hypertensive patients with ventricular hypertrophy. J Hypertens 26: 553-559.
59. Teniente-Valente, R., Solorio, S., Vargas-Salado, E., Aguirre-Vazquez, C., Hernandez-Gonzalez, M.A., Olvera-Lopez, J.A. et al. (2008) Improvement of diastolic function after regression of left ventricular hypertrophy. Arch Cardiol Mex 78: 392-399.
60. Thomas, J.D. and Weyman, A.E. (1991) Echocardiographic Doppler evaluation of left ventricular diastolic function. Physics and physiology. Circulation 84: 977-990.
61. Tsuyuki, R.T., Yusuf, S., Rouleau, J.L., Maggioni, A.P., McKelvie, R.S., Wiecek, E.M. et al. (1997) Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 13: 1166-1174.
62. van den Meiracker, A.H., Man in ‘t Veld, A.J., Admiraal, P.J., Ritsema van Eck, H.J., Boomsma, F., Derkx, F.H. et al. (1992) Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 10: 803-812.
63. Varo, N., Etayo, J.C., Zalba, G., Beaumont, J., Iraburu, M.J., Montiel, C. et al. (1999) Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17: 107-114.
64. Varo, N., Iraburu, M.J., Varela, M., Lopez, B., Etayo, J.C. and Diez, J. (2000) Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 35: 1197-1202.
65. Wachtell, K., Smith, G., Gerdts, E., Dahlof, B., Nieminen, M.S., Papademetriou, V. et al. (2000) Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint. Am J Cardiol 85: 466-472.
66. Weber, K.T., Janicki, J.S., Pick, R., Abrahams, C., Shroff, S.G., Bashey, R.I. et al. (1987) Collagen in the hypertrophied, pressure-overloaded myocardium. Circulation 75: 140-147.
67. Werner, C., Baumhakel, M., Teo, K.K., Schmieder, R., Mann, J., Unger, T. et al. (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97: 418-431.
68. Williams, B., Poulter, N.R., Brown, M.J., Davis, M., McInnes, G.T., Potter, J.F. et al. (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18: 139-185.
69. Yamaleyeva, L.M., Gallagher, P.E., Vinsant, S. and Chappell, M.C. (2007 a) Discoordinate regulation of renal nitric oxide synthase isoforms in ovariectomized mRen2.Lewis rats. Am J Physiol Regul Integr Comp Physiol 292: R819-R826.
70. Yamaleyeva, L.M., Pendergrass, K.D., Pirro, N.T., Gallagher, P.E., Groban, L. and Chappell, M.C. (2007 b) Ovariectomy is protective against renal injury in the high-salt-fed older mRen2.Lewis rat. Am J Physiol Heart Circ Physiol 293: H2064-H2071.
71. Yoshida, J., Yamamoto, K., Mano, T., Sakata, Y., Nishikawa, N., Nishio, M. et al. (2004) AT 1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 43: 686-691.
72. Yusuf, S., Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J. et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777-781.